Michael Yu, Innovent CEO
Innovent showcases topline PhII win for high-dose obesity drug in China
Innovent is offering up a fresh look at its obesity drug candidate, showcasing an average 15.4% placebo-adjusted weight loss after 24 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.